Table 2.
Comparison between eyes with and without hyperreflective foci.
| HRF (+) (n = 53) |
HRF (−) (n = 102) |
p-value | |
|---|---|---|---|
| Age(years) | 78.8 ± 7.6 | 77.3 ± 7.6 | 0.22 |
| Females | 14 (26.4%) | 38 (37.3%) | 0.18 |
| Presence of pseudodrusen | 32 (60.4%) | 32 (31.4%) | 5.0 × 10−4 |
| Presence of DPED | 29 (54.7%) | 14 (13.7%) | 6.4 × 10−8 |
| Subfoveal choroidal thickness | 189 ± 86 | 226 ± 88 | 0.013 |
| MNV subtype in the contralateral eye | |||
| Type 3 MNV | 17 (32.1%) | 6 (5.9%) | 1.0 × 10−5 |
| Typical neovascular AMD | 28 (52.8%) | 54 (52.9%) | 0.99 |
| PCV | 8 (15.1%) | 42 (41.2%) | 9.8 × 10−4 |
| T allele frequency of ARMS2 A69S | 81.1% | 69.1% | 0.023 |
| G allele frequency of CFH I62Vj | 78.3% | 76.0% | 0.65 |
HRF, hyperreflective foci; DPED, drusenoid pigment epithelial detachment; MNV, macular neovascularization; RAP, retinal angiomatous proliferation.